flupenthixol

Significantly increased risk of severe QTc prolongation and potentially fatal arrhythmias (e.g., Torsades de Pointes). Both are potent QTc prolonging agents.

Concomitant use is contraindicated due to high risk of severe cardiac adverse events.

Increased sedation, drowsiness, impaired psychomotor function, and respiratory depression.

Advise patients to avoid alcohol consumption while taking flupenthixol.

Increased risk of QTc prolongation and potentially life-threatening arrhythmias (e.g., Torsades de Pointes). Also, increased flupenthixol levels due to CYP2D6 inhibition.

Avoid concomitant use if possible. If unavoidable, monitor ECG closely for QTc prolongation. Consider lower doses of flupenthixol and monitor for increased adverse effects. Correct electrolyte imbalances.

Increased sedation, drowsiness, and respiratory depression.

Use with caution. Monitor for excessive sedation. Consider lower doses of both drugs. Advise patients about potential for increased drowsiness.

Decreased plasma concentrations and therapeutic effect of flupenthixol, potentially leading to symptom exacerbation.

Monitor for reduced efficacy of flupenthixol. Consider increasing flupenthixol dose or using an alternative anticonvulsant if possible. Therapeutic drug monitoring for flupenthixol may be beneficial.

Increased plasma concentrations of flupenthixol, potentially leading to increased risk of adverse effects such as extrapyramidal symptoms, QTc prolongation, and sedation.

Monitor for increased adverse effects of flupenthixol. Consider reducing flupenthixol dose. Therapeutic drug monitoring for flupenthixol may be beneficial.

Increased risk of QTc prolongation, extrapyramidal symptoms (EPS), and sedation. Both are dopamine receptor blockers.

Avoid concomitant use if possible. If unavoidable, monitor ECG for QTc prolongation and observe closely for EPS and excessive sedation. Consider lower doses of both drugs.

Reduced efficacy of levodopa in treating Parkinson's disease symptoms, leading to worsening of motor symptoms.

Avoid concomitant use if possible. If unavoidable, monitor for worsening Parkinson's symptoms. Consider alternative antipsychotics with less dopamine receptor blockade (e.g., clozapine, quetiapine) if antipsychotic treatment is essential.

Increased risk of extrapyramidal symptoms (EPS) due to additive dopamine receptor blockade.

Avoid concomitant use if possible. If unavoidable, monitor closely for EPS. Consider alternative antiemetics.

Increased plasma concentrations of flupenthixol, potentially leading to increased risk of adverse effects such as extrapyramidal symptoms, QTc prolongation, and sedation.

Monitor for increased adverse effects of flupenthixol. Consider reducing flupenthixol dose. Therapeutic drug monitoring for flupenthixol may be beneficial.

Decreased plasma concentrations and therapeutic effect of flupenthixol, potentially leading to symptom exacerbation.

Monitor for reduced efficacy of flupenthixol. Consider increasing flupenthixol dose or using an alternative anticonvulsant if possible. Therapeutic drug monitoring for flupenthixol may be beneficial.

Increased plasma concentrations of flupenthixol, potentially leading to increased risk of adverse effects such as extrapyramidal symptoms, QTc prolongation, and sedation.

Monitor for increased adverse effects of flupenthixol. Consider reducing flupenthixol dose. Therapeutic drug monitoring for flupenthixol may be beneficial.